 |
|
Incomplete Financial Disclosure for Study of Funding and Outcomes in Major Cardiovascular Trials
|
|
| Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings. |
|
|
|
To the Editor: I would like to apologize to the readers of JAMA for an incomplete financial disclosure in my article on reported outcomes in major cardiovascular clinical trials funded by for-profit and not-for-profit organizations.1 My coauthor and I received no financial or material support of any kind from any entity for this study. In the article, we described the funding source and outcome for those cardiovascular trials surveyed in which I served as either the primary author or coauthor.2-5
However, JAMA policy requires disclosure of any potential conflicts of interest even when there is no funding for the study at hand. This policy does not distinguish whether or not the conclusions are unfavorable to the entities involved. In this regard, over the past 5 years I have received research funding from multiple not-for-profit entities including the National Heart, Lung, and Blood Institute, the Doris Duke Charitable Foundation, the Leducq . . . [Full Text of this Article]
Paul M Ridker, MD
pridker@partners.org
Brigham and Women's Hospital
Boston, Mass
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
RELATED ARTICLE
Reported Outcomes in Major Cardiovascular Clinical Trials Funded by For-Profit and Not-for-Profit Organizations: 2000-2005
Paul M Ridker and Jose Torres
JAMA. 2006;295(19):2270-2274.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Resolving Unreported Conflicts of Interest
DeAngelis and Fontanarosa
JAMA 2009;302:198-199.
FULL TEXT
The Influence of Money on Medical Science
DeAngelis
JAMA 2006;296:996-998.
FULL TEXT
Update on JAMA's Conflict of Interest Policy.
Flanagin et al.
JAMA 2006;296:220-221.
FULL TEXT
|
